These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25908996)

  • 41. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
    Rodriguez-Barradas MC; Groover JE; Lacke CE; Gump DW; Lahart CJ; Pandey JP; Musher DM
    J Infect Dis; 1996 Jun; 173(6):1347-53. PubMed ID: 8648206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
    Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
    J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistence of Hepatitis B Immunity Following 3-dose Infant Primary Series in HIV-infected Thai Adolescents and Immunologic Response to Revaccination.
    Lapphra K; Angkhananukit P; Saihongthong S; Phongsamart W; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
    Pediatr Infect Dis J; 2017 Sep; 36(9):863-868. PubMed ID: 28419007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults.
    Kroon FP; van Dissel JT; Ravensbergen E; Nibbering PH; van Furth R
    Vaccine; 2000 Nov; 19(7-8):886-94. PubMed ID: 11115712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines.
    O'Brien KL; Steinhoff MC; Edwards K; Keyserling H; Thoms ML; Madore D
    Pediatr Infect Dis J; 1996 May; 15(5):425-30. PubMed ID: 8724065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immunological effect of vaccination against pneumococcal infection in HIV-infected children].
    Pakhomov DV; Kostinov MP; Poddubikov AV; Vaneeva NP; Snegova NF; Nikitina TN; Zinkina TN; Suloeva SV
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):48-52. PubMed ID: 19459477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy.
    Montoya CJ; Toro MF; Aguirre C; Bustamante A; Hernandez M; Arango LP; Echeverry M; Arango AE; Prada MC; Alarcon Hdel P; Rojas M
    Mem Inst Oswaldo Cruz; 2007 Jun; 102(4):501-8. PubMed ID: 17612772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
    Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
    Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children.
    Obaro SK; Huo Z; Banya WA; Henderson DC; Monteil MA; Leach A; Greenwood BM
    Pediatr Infect Dis J; 1997 Dec; 16(12):1135-40. PubMed ID: 9427458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects.
    Huang H; Qian X; Pan R; Shen L; Liang S; Wang F; Zhang P; Shen H; Chen ZW
    Clin Immunol; 2018 Aug; 193():1-9. PubMed ID: 29753126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.
    Cheng A; Chang SY; Tsai MS; Su YC; Liu WC; Sun HY; Hung CC
    J Int AIDS Soc; 2016; 19(1):20631. PubMed ID: 26829360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.
    Hesselstrand R; Nagel J; Saxne T; Geborek P; Skattum L; Kapetanovic MC
    Rheumatology (Oxford); 2018 Apr; 57(4):625-630. PubMed ID: 29325173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.
    Grabar S; Groh M; Bahuaud M; Le Guern V; Costedoat-Chalumeau N; Mathian A; Hanslik T; Guillevin L; Batteux F; Launay O;
    Vaccine; 2017 Sep; 35(37):4877-4885. PubMed ID: 28784280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.